163 related articles for article (PubMed ID: 18216299)
1. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy.
Zhou P; Comenzo RL; Olshen AB; Bonvini E; Koenig S; Maslak PG; Fleisher M; Hoffman J; Jhanwar S; Young JW; Nimer SD; Boruchov AM
Blood; 2008 Apr; 111(7):3403-6. PubMed ID: 18216299
[TBL] [Abstract][Full Text] [Related]
2. CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.
Rankin CT; Veri MC; Gorlatov S; Tuaillon N; Burke S; Huang L; Inzunza HD; Li H; Thomas S; Johnson S; Stavenhagen J; Koenig S; Bonvini E
Blood; 2006 Oct; 108(7):2384-91. PubMed ID: 16757681
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
Veri MC; Gorlatov S; Li H; Burke S; Johnson S; Stavenhagen J; Stein KE; Bonvini E; Koenig S
Immunology; 2007 Jul; 121(3):392-404. PubMed ID: 17386079
[TBL] [Abstract][Full Text] [Related]
4. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis.
Zhou P; Hoffman J; Landau H; Hassoun H; Iyer L; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):49-58. PubMed ID: 22100494
[TBL] [Abstract][Full Text] [Related]
5. Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan.
Zhou P; Teruya-Feldstein J; Lu P; Fleisher M; Olshen A; Comenzo RL
Blood; 2008 Jan; 111(2):549-57. PubMed ID: 17982021
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.
Lisenko K; Schönland SO; Jauch A; Andrulis M; Röcken C; Ho AD; Goldschmidt H; Hegenbart U; Hundemer M
Cancer Med; 2016 Jul; 5(7):1464-72. PubMed ID: 27109862
[TBL] [Abstract][Full Text] [Related]
7. Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies.
Lu H; Molony RD; Chen D; Jang S; Wolf B; Ewert S; Flaherty M; Xu F; Isim S; Shim Y; Dornelas C; Balke N; Leber XC; Scharenberg M; Koelln J; Choi E; Ward R; Johnson J; Calzascia T; Isnardi I; Williams JA; Lindenbergh PL; van de Donk NWCJ; Mutis T; Huet H; Lees E; Meyer MJ
Mol Cancer Ther; 2020 Oct; 19(10):2089-2104. PubMed ID: 32847974
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of miRNAs in AL amyloidosis.
Weng L; Spencer BH; SoohHoo PT; Connors LH; O'Hara CJ; Seldin DC
Amyloid; 2011 Sep; 18(3):128-35. PubMed ID: 21834602
[TBL] [Abstract][Full Text] [Related]
9. AL amyloidosis with a localized B cell neoplasia.
Stuhlmann-Laeisz C; Schönland SO; Hegenbart U; Oschlies I; Baumgart JV; Krüger S; Röcken C
Virchows Arch; 2019 Mar; 474(3):353-363. PubMed ID: 30680453
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of clonal bone marrow CD19+ B cells: use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis.
Manske MK; Zuckerman NS; Timm MM; Maiden S; Edelman H; Shahaf G; Barak M; Dispenzieri A; Gertz MA; Mehr R; Abraham RS
Clin Immunol; 2006 Jul; 120(1):106-20. PubMed ID: 16515886
[TBL] [Abstract][Full Text] [Related]
11. Potential therapeutic targets in plasma cell disorders: A flow cytometry study.
Lisenko K; Schönland S; Hegenbart U; Wallenwein K; Braun U; Mai EK; Hillengass J; Goldschmidt H; Jauch A; Ho AD; Raab M; Hundemer M
Cytometry B Clin Cytom; 2017 Mar; 92(2):145-152. PubMed ID: 26666746
[TBL] [Abstract][Full Text] [Related]
12. Splenic plasma cells can serve as a source of amyloidogenic light chains.
Solomon A; Macy SD; Wooliver C; Weiss DT; Westermark P
Blood; 2009 Feb; 113(7):1501-3. PubMed ID: 19050307
[TBL] [Abstract][Full Text] [Related]
13. Analysis of plasma cell clonality in localized AL amyloidosis.
Setoguchi M; Hoshii Y; Kawano H; Ishihara T
Amyloid; 2000 Mar; 7(1):41-5. PubMed ID: 10842704
[TBL] [Abstract][Full Text] [Related]
14. A reappraisal of immunoglobulin variable gene primers and its impact on assessing clonal relationships between PB B cells and BM plasma cells in AL amyloidosis.
Katoh N; Poshusta TL; Manske MK; Dispenzieri A; Gertz MA; Abraham RS; Ramirez-Alvarado M
J Clin Immunol; 2011 Dec; 31(6):1029-37. PubMed ID: 21909811
[TBL] [Abstract][Full Text] [Related]
15. Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis.
Roccatello D; Fenoglio R; Baldovino S; Naretto C; Ferro M; Barreca A; Rossi D; Sciascia S
Autoimmun Rev; 2020 Sep; 19(9):102622. PubMed ID: 32663622
[TBL] [Abstract][Full Text] [Related]
16. Two distinct syndromes of lymphoma-associated AL amyloidosis: a case series and review of the literature.
Telio D; Bailey D; Chen C; Crump M; Reece D; Kukreti V
Am J Hematol; 2010 Oct; 85(10):805-8. PubMed ID: 20872959
[TBL] [Abstract][Full Text] [Related]
17. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
van Velzen JF; van den Blink D; Bloem AC
Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187
[TBL] [Abstract][Full Text] [Related]
18. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
19. Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production.
Laeng RH; Altermatt HJ; Scheithauer BW; Zimmermann DR
Cancer; 1998 Jan; 82(2):362-74. PubMed ID: 9445195
[TBL] [Abstract][Full Text] [Related]
20. Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody.
Vervoordeldonk SF; Merle PA; van Leeuwen EF; van der Schoot CE; von dem Borne AE; Slaper-Cortenbach IC
Blood; 1994 Mar; 83(6):1632-9. PubMed ID: 7510146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
